Among active 13F managers last quarter, 7 opened and 1 reduced; the largest holder to move was Caligan Partners LP (new position). Over the last 180 days, 2 insiders bought and none sold, a net +$50K in open-market trades.
Funds lean in and no leg opposes.
23 tracked 13F filers disclose a position in CLRB as of the latest SEC 13F filings, a combined $6.3M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Caligan Partners LP | 470K | $1.3M | ▲New +470K sh | Q2 2026 | |
| 2 | Stempoint Capital LP | 355K | $987K | ▲New +355K sh | Q2 2026 | |
| 3 | Vanguard Capital Management LLC | 327K | $910K | ▲+300% Added · +245K sh | Q2 2026 | |
| 4 | Silverarc Capital Management, LLC | 322K | $894K | ▲New +322K sh | Q2 2026 | |
| 5 | Nantahala Capital Management, LLC | 220K | $612K | ▲New +220K sh | Q2 2026 | |
| 6 | Diadema Partners LP | 138K | $385K | ▲New +138K sh | Q2 2026 | |
| 7 | Stonepine Capital Management, LLC | 105K | $291K | ▲New +105K sh | Q2 2026 | |
| 8 | Persistent Asset Partners Ltd | 93K | $258K | ▲New +93K sh | Q2 2026 | |
| 9 | Boothbay Fund Management, LLC | 85K | $236K | ▲New +85K sh | Q2 2026 | |
| 10 | Geode Capital Management, LLC | 53K | $148K | ▲+1.1% Added · +573 sh | Q2 2026 | |
| 11 | Vanguard Fiduciary Trust Co | 46K | $128K | ▲+179% Added · +30K sh | Q2 2026 | |
| 12 | Sequoia Financial Advisors, LLC | 22K | $61K | ▲+16% Added · +3K sh | Q2 2026 | |
| 13 | Riverview Capital Advisers, LLC | 10K | $50K | —Held | Q2 2026 | |
| 14 | UBS Group AG | 10K | $25K | ▲+271% Added · +7K sh | Q1 2026 | |
| 15 | BlackRock, Inc. | 5K | $13K | ▼−0.2% Reduced · −10 sh | Q2 2026 | |
| 16 | Tower Research Capital LLC (TRC) | 793 | $2K | ▼−57% Reduced · −1K sh | Q1 2026 | |
| 17 | Morgan Stanley | 510 | $1K | —Held | Q1 2026 | |
| 18 | TD Waterhouse Canada Inc. | 63 | $178 | —Held | Q2 2026 | |
| 19 | SBI Securities Co., Ltd. | 11 | $31 | —Held | Q2 2026 | |
| 20 | Jones Financial Companies LLLP | 3 | $8 | —Held | Q1 2026 | |
| 21 | US Bancorp | 3 | $8 | —Held | Q1 2026 | |
| 22 | Danske Bank A/s | 2 | $6 | —Held | Q2 2026 | |
| 23 | Osaic Holdings, Inc. | 1 | $2 | ▼−86% Reduced · −6 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 7 funds opened a new position in CLRB, while 1 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Revolution Medicines IncRVMD | 7 funds | $494.4M |
| Abivax Sa-ADRABVX | 7 funds | $366.9M |
| Vaxcyte IncPCVX | 7 funds | $181.2M |
| Tango Therapeutics IncTNGX | 7 funds | $148.2M |
| Uniqure NVQURE | 7 funds | $31.7M |
| LB Pharmaceuticals IncLBRX | 6 funds | $91.0M |
| Adma Biologics IncADMA | 6 funds | $84.0M |
| Xenon Pharmaceuticals IncXENE | 6 funds | $81.1M |
| Aura Biosciences IncAURA | 6 funds | $63.0M |
| Dianthus Therapeutics IncDNTH | 6 funds | $59.3M |
| Monte Rosa Therapeutics IncGLUE | 6 funds | $47.2M |
| Oruka Therapeutics IncORKA | 6 funds | $46.2M |
Ranked by how many of CLRB's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in CLRB.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 7, 2026 | Caruso James V | Chief Executive Officer, Director | Buy (P) | 9K | $25K |
| May 7, 2026 | Longcor Jarrod | Chief Operating Officer | Buy (P) | 9K | $25K |
| Dec 12, 2025 | Neis John | Director | Sell (S) | 198 | $733 |
| Jul 2, 2025 | Kolean Chad J | Chief Financial Officer | Buy (P) | 5K | $25K |
| Jul 2, 2025 | Longcor Jarrod | Chief Operating Officer | Buy (P) | 10K | $50K |
| Jul 2, 2025 | Caruso James V | Chief Executive Officer, Director | Buy (P) | 10K | $50K |
| Jan 10, 2025 | Longcor Jarrod | Chief Operating Officer | Buy (P) | 30K | $8K |
| Sep 14, 2021 | Swirsky Douglas J | Director | Buy (P) | 25K | $26K |
| Sep 3, 2021 | Driscoll Frederick W | Director | Buy (P) | 19K | $20K |
| Mar 4, 2021 | Caruso James V | President and CEO, Director | Buy (P) | 5K | $9K |
| Dec 28, 2020 | Elefant Dov | Chief Financial Officer | Buy (P) | 7K | $10K |
| Dec 28, 2020 | Longcor Jarrod | Chief Business Officer | Buy (P) | 30K | $40K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 5 | 3 | – |
Insiders Form 4 open-market | 2 | 0 | +$50K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for CLRB
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/CLRB/capital-change-brief"
Use Arkolith's capital_change_brief for CLRB. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for CLRB. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.